JP2021529829A5 - - Google Patents

Info

Publication number
JP2021529829A5
JP2021529829A5 JP2021522114A JP2021522114A JP2021529829A5 JP 2021529829 A5 JP2021529829 A5 JP 2021529829A5 JP 2021522114 A JP2021522114 A JP 2021522114A JP 2021522114 A JP2021522114 A JP 2021522114A JP 2021529829 A5 JP2021529829 A5 JP 2021529829A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
composition according
amount
per
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021522114A
Other languages
English (en)
Japanese (ja)
Other versions
JP7304944B2 (ja
JP2021529829A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2019/050881 external-priority patent/WO2020000092A1/en
Publication of JP2021529829A publication Critical patent/JP2021529829A/ja
Publication of JP2021529829A5 publication Critical patent/JP2021529829A5/ja
Application granted granted Critical
Publication of JP7304944B2 publication Critical patent/JP7304944B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021522114A 2018-06-27 2019-06-25 腎線維症又は腎疾患の予防又は治療におけるアクタリットの使用 Active JP7304944B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862690738P 2018-06-27 2018-06-27
US62/690,738 2018-06-27
US201962809330P 2019-02-22 2019-02-22
US62/809,330 2019-02-22
PCT/CA2019/050881 WO2020000092A1 (en) 2018-06-27 2019-06-25 The use of actarit in the prophylaxis or treatment of renal fibrosis or kidney disease

Publications (3)

Publication Number Publication Date
JP2021529829A JP2021529829A (ja) 2021-11-04
JP2021529829A5 true JP2021529829A5 (https=) 2022-07-06
JP7304944B2 JP7304944B2 (ja) 2023-07-07

Family

ID=68985352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021522114A Active JP7304944B2 (ja) 2018-06-27 2019-06-25 腎線維症又は腎疾患の予防又は治療におけるアクタリットの使用

Country Status (6)

Country Link
US (1) US12280026B2 (https=)
EP (2) EP4046633A1 (https=)
JP (1) JP7304944B2 (https=)
CN (1) CN112423742B (https=)
CA (1) CA3105127A1 (https=)
WO (1) WO2020000092A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3920921A4 (en) * 2019-02-07 2022-11-02 Alsatech, Inc. POLYVALENT EMOXYPIN DERIVATIVES
WO2020191503A1 (en) * 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bromantane and derivatives thereof for treating lung disease, fatty liver disease, and kidney disorders
WO2020191501A1 (en) * 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bemithyl and derivatives for treating lung disease, fatty liver disease, and kidney disorders
WO2020191502A1 (en) * 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Use of emoxypine and derivatives thereof for treating kidney disorders and inflammatory bowel disease
CN113368106B (zh) * 2020-02-25 2023-09-29 渐宽(苏州)生物科技有限公司 艾托莫德用于防治特发性肺纤维化的药物中的用途
IT202100014177A1 (it) * 2021-05-31 2022-12-01 Sunnutrapharma S R L Utilizzo della istradefillina per ridurre la fibrosi d’organo
EP4734971A2 (en) * 2023-08-09 2026-05-06 Single Dose Therapeutics, Inc. Drug to treat stimulant addiction

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU1601978C (ru) * 1988-12-29 1995-10-27 Научно-исследовательский институт фармакологии РАМН Способ получения n-(4-бромфенил)-n-(2-адамантил)амина
RU2109727C1 (ru) * 1994-06-10 1998-04-27 Научно-исследовательский институт фармакологии РАМН Способ получения адамантан-2-она
US7138140B2 (en) * 2001-04-16 2006-11-21 Taiho Pharmaceutical Co., Ltd. Suplatast tosilate crystals
JP2005089345A (ja) * 2003-09-16 2005-04-07 Tendou Seiyaku Kk 虫刺され治療薬
US7838552B2 (en) * 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
JP4794148B2 (ja) * 2004-09-10 2011-10-19 大鵬薬品工業株式会社 ネフローゼ症候群治療剤
KR101390563B1 (ko) * 2005-01-31 2014-04-30 밀란 인크. 글루쿠로니드화된 네비볼롤
US20090054381A1 (en) * 2005-10-04 2009-02-26 Nitromed, Inc. Methods for treating respiratory disorders
AU2007339153B2 (en) * 2006-12-26 2010-11-25 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for diabetic neuropathy
US8975409B2 (en) * 2011-09-29 2015-03-10 Ono Pharmaceutical Co., Ltd. Phenyl derivative
US20160250238A1 (en) * 2013-10-03 2016-09-01 Millennium Pharmaceuticals, Inc. Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis
WO2017032384A1 (en) * 2015-08-25 2017-03-02 Conrig Pharma Aps Compound and use in the treatment of cough
EP3393463B1 (en) * 2015-12-23 2021-01-20 Conrig Pharma ApS Suplatast tosilate for treating cough associated with interstitial lung disease
EP3556673B1 (en) 2018-04-20 2023-10-11 Tetra Laval Holdings & Finance S.A. A sealed package containing a pourable food product and a sheet packaging material for producing a sealed package containing a pourable food product

Similar Documents

Publication Publication Date Title
JP2021529829A5 (https=)
JP2023041862A5 (https=)
JP2023503309A5 (https=)
JP2023503303A5 (https=)
JP2018193377A5 (https=)
JP2023503068A5 (https=)
JP2017149726A5 (https=)
JP2012193216A5 (https=)
JP2010522242A5 (https=)
JP2016163571A5 (https=)
JP2017506624A5 (https=)
JP2016518337A5 (https=)
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2017526651A5 (https=)
CN111989095A (zh) 预防或治疗肿瘤疗法副作用的方法
JPWO2023195530A5 (https=)
JP2024512425A5 (https=)
JP2015537009A5 (https=)
MX2020012377A (es) Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.
JP2016530291A5 (https=)
JP2009541409A5 (https=)
JP2016527312A5 (ja) ヒスタミンｈ４受容体を介してもたらされた掻痒状態を治療するための医薬組成物
JP2021535175A5 (https=)
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use